Edoxaban tosylate monohydrateOral factor Xa inhibitor CAS# 1229194-11-9 |
- Ruscogenin
Catalog No.:BCN6287
CAS No.:472-11-7
- Pectolinarigenin
Catalog No.:BCN5813
CAS No.:520-12-7
- Dauricine
Catalog No.:BCN4977
CAS No.:524-17-4
- Oroxin A
Catalog No.:BCN1202
CAS No.:57396-78-8
- Triptophenolide
Catalog No.:BCN2546
CAS No.:74285-86-2
- Wilforlide A
Catalog No.:BCN4383
CAS No.:84104-71-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1229194-11-9 | SDF | Download SDF |
| PubChem ID | 25022378 | Appearance | Powder |
| Formula | C31H40ClN7O8S2 | M.Wt | 738.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 50 mg/mL (67.73 mM; Need ultrasonic) H2O : 1 mg/mL (1.35 mM; Need ultrasonic) | ||
| Chemical Name | N'-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide;4-methylbenzenesulfonic acid;hydrate | ||
| SMILES | CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCC2=C(C1)SC(=N2)C(=O)NC3CC(CCC3NC(=O)C(=O)NC4=NC=C(C=C4)Cl)C(=O)N(C)C.O | ||
| Standard InChIKey | PSMMNJNZVZZNOI-SJILXJHISA-N | ||
| Standard InChI | InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Edoxaban(DU-176) is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention
IC50 Value:
Target: factor Xa
Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) and/or nonsteroidal anti-inflammatory drugs for concurrent illnesses[1].
in vitro: Edoxaban PK was not affected by concomitant low-dose ASA or naproxen, but high-dose ASA increased systemic exposure of edoxaban by approximately 30%. The effects of edoxaban on prothrombin time, activated partial thromboplastin time, international normalized ratio, anti-FXa, and intrinsic FXa activity were not influenced by administration with ASA or naproxen. Inhibition of platelet aggregation by high-dose ASA, low-dose ASA, or naproxen was not affected by edoxaban[1].
in vivo: Forty-eight subjects, aged 18 to 45 years, received either edoxaban 60 mg once daily × 7 days (n = 24) or digoxin 0.25 mg twice daily × 2 days and once daily × 5 days (n = 24) and then concomitantly for 7 days. Serial blood and urine samples were collected for digoxin and edoxaban concentrations on days 7 and 14. Serial coagulation assays were measured for edoxaban on days 7 and 14. Edoxaban PK parameters demonstrated mild increases in area under the curve and peak concentrations of 9.5% and 15.6%, respectively[2],
Clinical trial: Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans was reported[3]. References: | |||||
Edoxaban tosylate monohydrate Dilution Calculator
Edoxaban tosylate monohydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.3545 mL | 6.7726 mL | 13.5452 mL | 27.0904 mL | 33.8629 mL |
| 5 mM | 0.2709 mL | 1.3545 mL | 2.709 mL | 5.4181 mL | 6.7726 mL |
| 10 mM | 0.1355 mL | 0.6773 mL | 1.3545 mL | 2.709 mL | 3.3863 mL |
| 50 mM | 0.0271 mL | 0.1355 mL | 0.2709 mL | 0.5418 mL | 0.6773 mL |
| 100 mM | 0.0135 mL | 0.0677 mL | 0.1355 mL | 0.2709 mL | 0.3386 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Factor Xa (FXa), a key serine protease, is a promising target enzyme for the prophylaxis and treatment of thromboembolic diseases. Edoxaban tosylate monohydrate is a novel antithrombotic agent that directly inhibits FXa activity.
In vitro: Edoxaban tosylate monohydrate (DU-176b) inhibited FXa with Ki values of 0.561 nM for free FXa, 2.98 nM for prothrombinase, and exhibited >10 000-fold selectivity for FXa. DU-176b doubled prothrombin time and activated partial thromboplastin time in human plasma. DU-176b did not impair platelet aggregation by ADP, collagen or U46619 [1].
In vivo: DU-176b dose-dependently inhibited thrombus formation in rat and rabbit thrombosis models, although bleeding time in rats was not significantly prolonged at an antithrombotic dose [1].
Clinical trial: A previous study determined the mass balance and pharmacokinetics of edoxaban in humans after oral administration of [14C]edoxaban. The mass balance of edoxaban study showed unchanged edoxaban as the most abundant component. Edoxaban was eliminated through multiple pathways, but each accounts for only a small amount of overall elimination [2].
References:
[1] Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, Morishima Y, Shibano T. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6(9):1542-9.
[2] Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40(12):2250-5.
- 3-O-Acetylandrostenone hydrazone
Catalog No.:BCC8637
CAS No.:122914-94-7
- GSK 9027
Catalog No.:BCC6115
CAS No.:1229096-88-1
- Tatarinoid A
Catalog No.:BCN6119
CAS No.:1229005-35-9
- 12-Demethylneocaesalpin F
Catalog No.:BCN6410
CAS No.:1228964-10-0
- MLN0905
Catalog No.:BCC3961
CAS No.:1228960-69-7
- Ziprasidone HCl
Catalog No.:BCC2511
CAS No.:122883-93-6
- Mps1-IN-2
Catalog No.:BCC4153
CAS No.:1228817-38-6
- 2-Desoxy-4-epi-pulchellin
Catalog No.:BCN6118
CAS No.:122872-03-1
- AM-095 free base
Catalog No.:BCC1352
CAS No.:1228690-36-5
- AM966
Catalog No.:BCC1355
CAS No.:1228690-19-4
- TAK-632
Catalog No.:BCC3639
CAS No.:1228591-30-7
- GS-9620
Catalog No.:BCC1602
CAS No.:1228585-88-3
- GS-9973
Catalog No.:BCC5278
CAS No.:1229208-44-9
- C 21
Catalog No.:BCC8013
CAS No.:1229236-78-5
- LY2784544
Catalog No.:BCC2200
CAS No.:1229236-86-5
- Fmoc-L-Beta-Homoproline
Catalog No.:BCN8087
CAS No.:193693-60-6
- N-(3-Methoxybenzyl)palmitamide
Catalog No.:BCN8086
CAS No.:847361-96-0
- XE 991 dihydrochloride
Catalog No.:BCC7232
CAS No.:122955-13-9
- URMC-099
Catalog No.:BCC5563
CAS No.:1229582-33-5
- 6'-O-Galloyl paeoniflorin
Catalog No.:BCN2941
CAS No.:122965-41-7
- HA 130
Catalog No.:BCC7884
CAS No.:1229652-21-4
- RG7388
Catalog No.:BCC1895
CAS No.:1229705-06-9
- Fmoc-Hyp(tBu)-OH
Catalog No.:BCC3256
CAS No.:122996-47-8
- 4-Hydroxybenzaldehyde
Catalog No.:BCN5816
CAS No.:123-08-0
